As of 2026-03-18, the Intrinsic Value of Bristol-Myers Squibb Co (BMY) is 76.76 USD. This Bmy valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 59.37 USD, the upside of Bristol-Myers Squibb Co is 29.30%.
The range of the Intrinsic Value is 53.93 - 126.41 USD
Based on its market price of 59.37 USD and our intrinsic valuation, Bristol-Myers Squibb Co (BMY) is undervalued by 29.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 53.93 - 126.41 | 76.76 | 29.3% |
| DCF (Growth 10y) | 60.20 - 128.78 | 81.98 | 38.1% |
| DCF (EBITDA 5y) | 37.89 - 46.19 | 41.53 | -30.0% |
| DCF (EBITDA 10y) | 47.21 - 58.85 | 52.41 | -11.7% |
| Fair Value | 86.61 - 86.61 | 86.61 | 45.88% |
| P/E | 62.15 - 85.83 | 72.68 | 22.4% |
| EV/EBITDA | 46.28 - 72.66 | 61.26 | 3.2% |
| EPV | 129.99 - 170.68 | 150.34 | 153.2% |
| DDM - Stable | 29.45 - 76.30 | 52.88 | -10.9% |
| DDM - Multi | 46.97 - 87.89 | 60.59 | 2.1% |
| Market Cap (mil) | 120,905.23 |
| Beta | 0.54 |
| Outstanding shares (mil) | 2,036.47 |
| Enterprise Value (mil) | 155,807.22 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.16% |
| Cost of Debt | 4.39% |
| WACC | 6.98% |